January 23-25, 2018

San Francisco, CA

REGISTER TO ATTEND NOW – SAVE $300

2018 Speakers

Expand/Collapse

Rafael Cubas Barcelli
Scientist
Genentech

Scientist at Genentech currently leading a translational research group supporting 8 cancer immunotherapy programs ranging from early discovery to late stage. My group provides in vivo pharmacology expertise to project teams during the discovery and development phases of biologics and small molecule drug discovery programs. We help define PK/PD/efficacy relationships in collaboration with colleagues within DMPK and Research Oncology. We also develop innovative preclinical mouse models that enable interrogation of mechanisms of action, diagnostic hypotheses, and mechanisms of resistance.

Day One

Wednesday January 24th, 2017

13.10 | Understanding T cell Exhaustion in Common Syngeneic Tumor Models

Shon Green
Preclinical Development
Eureka Therapeutics

Dr. Green’s expertise with preclinical models of cancer originate in her PhD work at UCSF where she studied the signaling pathways that drive lung cancer and melanoma. She joined Eureka Therapeutics Inc. in 2015 where she has been managing the preclinical development and IND-enabling research and operations for novel T cell-based immunotherapies. She has successfully guided two programs through in vivo proof-of-concept and safety studies to support INDs.

Day One

Wednesday January 24th, 2017

14.40 | Optimizing In Vivo Models for the Development of Autologous T cell Therapies

Svetlana Sadekova
Senior Principal Scientist
Merck

Day One

Wednesday January 24th, 2017

16.10 | Human Tissue Based Preclinical Models for Biomarker Discovery and Translational Research

Dan Rock
Executive Director
Amgen

Day Two

Thursday, January 25th 2018

10.10 | Understand Preclinical Pharmacokinetics and ADME of Bispecific T-cell Engagers

Barbara Joyce-Shaikh
Associate Principal Scientist
Merck

Ms. Joyce-Shaikh completed her B.S in molecular biology at San Jose State University. She has more than 20 years of biotech industry experience specializing in translational systems of immune function and immuno-oncology. Her work has contributed to several patents as well as peer-reviewed publications in several high-ranking international scientific journals including Nature, Immunity, Nature Medicine, and the Journal of Experimental Medicine. She is currently a project lead in the Discovery Immuno-oncology group at Merck Research Laboratories, in Palo Alto, California (formerly the DNAX Research Institute). Her research utilizes syngeneic and humanized mouse tumor systems to model tumor microenvironment with the goal of discovering novel immunomodulatory agents and combinatorial treatments to fight drug-resistant cancers.

Day One

Wednesday January 24th, 2017

16.40 | Humanized mouse models for drug discovery research

Kolin Hribar
CEO and Founder
Cypre, Inc

Kolin C. Hribar, PhD, is founder and CEO of Cypre Inc. Since its inception in 2016, Kolin has led a multi-disciplinary team in the development of their bioprinting platform and subsequent oncology collaborations with pharma and academia. The guiding mission at Cypre is to build a new set of 3D cell culture tools that enable scientists and clinical researchers in their pursuit of higher impact, complex phenotypic screening and patient-specific testing. Kolin received his PhD in Nanoengineering from UC San Diego and his Bachelors and Masters in Bioengineering from the University of Pennsylvania. He has published in peer-reviewed journals such as Nature Materials, Advanced Materials, ACS Nano, and Lab on a Chip.

Day One

Wednesday January 24th, 2017

12.10 | Utilising 3D Tumor Models Built With Scalable Bioprinting Technology to Improve Cancer Drug Development

Ruth Salmon
Sr. Director, In Vivo Pharmacology
Juno

Cinthia Pastuskovas
Senior Scientist
Amgen

Cinthia Pastuskovas obtained her Ph.D in Neuroscience in Argentina and did her post-doctoral training at the University of Iowa, USA. She was hired by Genentech Inc. in 2002 and transition to Amgen, Inc. in 2016. Cinthia is currently a senior scientist in the PKDM department and her area of eCinthia Pastuskovas obtained her Ph.D in Neuroscience in Argentina and did her post-doctoral training at the University of Iowa, USA. She was hired by Genentech Inc. in 2002 and transition to Amgen, Inc. in 2016. Cinthia is currently a senior scientist in the PKDM department and her area of expertise is the study of the ADME properties of large molecules. xpertise is the study of the ADME properties of large molecules.

Day Two

Thursday, January 25th 2018

09.40 | Characterization of ADME Properties of Novel Protein Therapeutics

Andrew Rhim
CPRIT Scholar in Cancer Research, Associate Director for Translational Research
in Pancreatic Cancer Research, MD Anderson Cancer Center

Day Two

Thursday, January 25th 2018

14.40 | Evaluating Preclinical Predictions for the Development of Combinations with Targeted Therapies & Immunotherapies

Dr. Abhishek Srivastava
Assistant Professor
University of Pittsburgh

Dr. Abhishek Srivastava is currently an Assistant Professor (Research) at Division of Surgical Oncology at University of Pittsburgh. His translational research involves the development of new immunotherapy strategies against advanced cancers. He received his PhD from University of Louisville, School of Medicine, USA. Dr. Srivastava also brings the pharmaceutical industry experience as he worked as Research Investigator to support the innovative immuno-oncology drug discovery pipeline for Bristol-Myers Squibb. Dr. Srivastava authored 30 plus research articles which include research articles, abstracts, book chapter and expert opinions.

Day One

Wednesday January 24th, 2017

12.40 | T Cell Co-Stimulation: A Potent Pathway for Improved Adoptive Cell Therapy

Mithun Khattar
Immuno-oncology lead
Takeda

Dr. Khattar is an immunologist at Takeda Pharmaceuticals, where he is leading efforts within cancer pharmacology to leverage the immune-phenotypic features of anti-cancer agents, and is engaged in designing next-generation approaches for cancer immunotherapy. Dr. Khattar’s previous research has focused on discovery of novel, antigen-specific immune therapies for cancer, autoimmunity and transplantation; involving modalities like CAR T-cells, personalized cancer vaccines, monoclonal antibodies and small molecule inhibitors. Prior to Takeda, he has held positions at Agenus Inc., Dana Farber Cancer Institute and Harvard Medical School. Dr. Khattar received his PhD in Immunology from the University of Toledo-Medical Center.

Day One

Wednesday January 24th, 2017

10.10 | Pre-clinical Modeling of Immune Responses to Cancer: From Bench-Side to Clinical Outcomes

Joshua Breunig
Assistant Professor
Cedars-Sinai Medical Center

Joshua Breunig, PhD, is an Assistant Professor at Cedars-Sinai Medical Center with a joint appointment in the Department of Medicine at the David Geffen School of Medicine at UCLA. Dr. Breunig received his Ph.D. from Yale University. Currently, he investigates the transcriptional regulation of neural precursor cells (NPCs) in the brain, specifically exploring the pathways governing the transformation of NPCs into brain tumor progenitors. Using a next generation brain tumor models, his lab introduces patient-specific mutations to create “personalized” tumors in immunocompetent animal models. Dr. Breunig is supported by funding from the American Cancer Society, and NIH/NCI.

Afternoon Workshop

Tuesday, January 23rd 2018

13.00 |

Models and methods for studying tumor heterogeneity and metastases

Day One

Wednesday January 24th, 2017

09.40 | Preclinical Modeling of Diverse Brain Tumor Subtypes via Single-Copy Somatic Transgenesis and CRISPR Genome Editing

Karen Spratt
Research Scientist
Seattle Children’s

As the head of IIH/BTCCCR pre-clinical therapeutic development, my group’s role is to develop and validate our therapeutic products for clinical trial.  I work closely with both the BTCCCR research groups and the clinical manufacturing group TCPC within SCRI.  Cellular and molecular in vitro assays as well as mouse model in vivo assays are performed to validate the CAR T cell therapeutic products.

Day Two

Thursday, January 25th 2018

14.10 | Multiplexing CAR T Cell Therapy

James Keck
Senior Director for the Clinical Lab & In Vivo Pharmacology Services
The Jackson Laboratory

Morning Workshop

Tuesday, January 23rd 2018

09.00 |

Humanized Mice for Immuno-Oncology

Day One

Wednesday January 24th, 2017

09.10 | Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

Toni Jun
Director of Scientific Engagement
Crown Bioscience

Dr. H. Toni Jun is currently a Director of Scientific Engagement at CrownBio with over 17 years of experience in biotech research. Dr. Jun worked at Kinetix Pharmaceuticals, a startup biotech focusing on small molecule kinase inhibitors for cancer and inflammation, AnaptysBio, working on both large molecule and bispecific immuno-oncology programs, and MabVax Therapeutics Holdings, Inc. where she coordinated both early stage clinical program efforts as well as late stage mAb discovery programs focusing on tumor associated carbohydrate antigens as targets. She also spent 11 years with Amgen both at the Cambridge site, leading small molecule kinase inhibitor programs, and later at the Thousand Oaks site, where she worked on antibody and large molecule modalities for cancer.  She has contributed to multiple patents and peer-reviewed publications throughout her career. Dr. Jun received her B.S. from the University of Michigan, Ann Arbor, and her Ph.D. in Virology from Harvard University, working at the Dana Farber Cancer Institute in Boston, MA.

Day One

Wednesday January 24th, 2017

10.40 | Developing checkpoint target humanized models for preclinical efficacy assessment

Dylan Daniel
Director - Scientific Development
MI Bioresearch

Day Two

Thursday, January 25th 2018

12.20 | Utilization of Murine Breast Cancer Models in Preclinical Immuno-Oncology Pharmacology

Neal Goodwin
Vice President, Corporate Research & Development
Champions Oncology

Day One

Wednesday January 24th, 2017

15.10 | Advanced PDX Tumor Biology Platforms for Drug Advancement

Mari Suominen
Research Director
Pharmatest

Day Two

Thursday, January 25th 2018

10.40 | Novel Bone Metastasis Models in Syngeneic and Humanized Mice

Mark Paris
Associate Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

Mark Paris is the technical lead for Mitra’s biopharma marketing effort and works with biopharma organizations to craft custom solutions for their drug development needs. He spent 16 years in commercial antibody discovery and clinical development focusing on immuno-oncology. Molecules discovered and developed under his direction are currently in Phase 2 clinical trials. Mark is a graduate of Case Western Reserve University with a PhD in Genetics, and a former fellow in the department of Cancer Biology at the Cleveland Clinic Foundation

Day Two

Thursday, January 25th 2018

9.10 | Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology

Simon Knott
Assistant Professor & Associate Director, Center for Bioinformatics and Functional Genomics
Cedars Sinai Medical Center

Simon Knott, PhD, is an assistant professor and associate director of the Center for Bioinformatics and Functional Genomics at Cedars Sinai Medical Center. Dr. Knott combines computational biology and functional genomics to elucidate the molecular mechanisms that drive cancer progression.  Work in his laboratory is focused on three main areas: heterogeneity in cancer cell populations and how it impacts disease outcome, hetero-cellular interactions that allow cancer cells to manipulate the tumor microenvironment to evade therapy, and the development of novel computational and molecular tools to study disease progression

Afternoon Workshop

Tuesday, January 23rd 2018

13.00 |

Models and methods for studying tumor heterogeneity and metastases

Maria Hristopoulos
Translational Oncology
Genentech

I received my Master of Science in Biotechnology degree from Johns Hopkins University. After joining the laboratory of Dr. Jeff Dodd-o at Johns Hopkins, my work focused primarily on in vivo mouse models of mechanical ventilation induced lung injury, including developing a novel mouse protocol to study the influence of mechanical ventilation-induced lung stretch on lung injury and kidney function. I joined the Department of Translational Oncology at Genentech in 2007. During this time, I have gained extensive experience developing different preclinical in vivo models to evaluate the efficacy of novel T cell therapies. Optimizing and understanding these mouse models made a significant impact advancing several Genentech T Cell Dependent Bispecific (TDB) antibody programs to clinical development

Day Two

Thursday, January 25th 2018

12.40 | Optimizing Preclinical Models for The Development of T Cell Dependent Bispecific (TDBs) Antibody Therapies Targeting Solid Tumors

Rafael Ponce
Sr. Director, Preclinical Sciences
Juno Therapeutics

Day Two

Thursday, January 25th 2018

11.50 | Strategies for Using Models In CAR T Cell Research and Development